Safety of high-dose naltrexone treatment: Hepatic transaminase profiles among outpatients

Suck Won Kim, Jon E. Grant, Gihyun Yoon, Kyle A. Williams, Rory P. Remmel

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.

Original languageEnglish (US)
Pages (from-to)77-79
Number of pages3
JournalClinical Neuropharmacology
Issue number2
StatePublished - Mar 2006


  • Alanine transaminase
  • Aspartate transaminase
  • Hepatotoxicity
  • Impulse-control disorders
  • Naltrexone
  • Nonsteroidal anti-inflammatory drugs
  • Pathologic gambling disorder


Dive into the research topics of 'Safety of high-dose naltrexone treatment: Hepatic transaminase profiles among outpatients'. Together they form a unique fingerprint.

Cite this